王凌斌;陆龙卫;赵凯;

• 1:浙江新安国际医院骨科

摘要(Abstract)：

唑来膦酸(ZOL)作为第三代二膦酸盐,较其他二膦酸盐类药物具有可静脉滴注,用药间隔长,消化道反应轻等优点,每年1次5 mg静脉滴注ZOL可有效提升骨质疏松患者的骨密度(BMD),降低脆性骨折的风险。ZOL也用于原发或转移性骨肿瘤,通过强力抑制肿瘤细胞诱导的骨溶解,减轻疼痛和骨破坏。ZOL可促进人工假体置入物与宿主骨整合,减少假体松动,延长其生存时间。此外,ZOL可减少软骨下骨再吸收与骨重建,保护骨的完整性,有可能成为股骨头坏死和骨性关节炎的辅助治疗药物。本文综述旨在复习近年来ZOL在骨科领域的相关研究与应用。

关键词(KeyWords)： 唑来膦酸;骨质疏松症;骨肿瘤;假体生物整合;骨性关节炎

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王凌斌;陆龙卫;赵凯;

Email:

DOI:

参考文献(References)：

• [1]Black DM,Delmus PD,Eastell R,et al.Once-yearly zoledranic acid for treatment of postmenopausal osteoporosis[J].N Engl J Med,2007,356(18):1809-1822.
• [2]Cramer JA,Gold DT.A systematic review of persistence and compliance with bisphosphonates for osteoporosis[J].Osteoporos Int,2007,18(8):1023-1031.
• [3]Dhillon S.Zoledronic Acid(Reclast(?),Aclasta(?)):a review in osteoporosis[J].Drugs,2016,76(17):1683-1697.
• [4]Durden E,Pinto L,Lopez-Gonzalez L,et al.Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States[J].Arch Osteoporos,2017,12(1):22.
• [5]Kong D,Chen Z.Evaluation of the interaction between hydroxyapatite and bisphosphonate by nonlinear capillary electrochromatography[J].J Sep Sci,2017,40(9):2030-2036.
• [6]Dempster DW,Roschger P,Misof BM,et al.Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ Study[J].J Bone Miner Res,2016,31(8):1527-1535.
• [7]Gokosmanoglu F,Varim C,Atmaca A,et al.The effects of zoledronic acid treatment on depression and quality of life in women with postmenopausal osteoporosis:a clinical trial study[J].J Res Med Sci,2016,21(2):112.
• [8]Ito M,Sone T,Shiraki M,et al.The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography(CT)in Japanese women with osteoporosis[J].Bone,2018,106(2):179-186.
• [9]刘玉涛.唑来膦酸治疗老年骨质疏松症的疗效观察[J].中医临床研究,2014,6(12):103-104.
• [10]Kachnic LA,Pugh SL,Boonen S,et al.Zoledronic acid prevents vertebral fractures in men with osteoporosis[J].Bonekey Rep,2013,6(2):294.
• [11]Misiorowski W.Osteoporosis in men[J].Prz Menopauzalny,2017,16(2):70-73.
• [12]Shiraki M,Tanaka S,Suzuki H,et al.Safety,pharmacokinetics,and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis[J].J Bone Miner Metab,2017,35(6):675-684.
• [13]Wang C.Efficacy and safety of zoledronic acid for treatment of postmenopausal osteoporosis:a meta-analysis of randomized controlled trials[J].Am J Ther,2017,24(5):544-552.
• [14]Yamakawa Y,Tazawa H,Hasei J,et al.Role of zoledronic acid in oncolytic virotherapy:promotion of antitumor effect and prevention of bone destruction[J].Cancer Sci,2017,108(9):1870-1880.
• [15]Labrinidis A,Hay S,Liapis V,et al.Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model[J].Clin Cancer Res,2009,15(10):3451-3461.
• [16]Ohba T,Cates JM,Cole HA,et al.Pleiotropic effects of bisphosphonates on osteosarcoma[J].Bone,2014,63(2):110-120
• [17]Arpornchayanon O,Leerapun T.Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor:a case report and review of the literature[J].J Med Assoc Thai,2008,91(10):1609-1612.
• [18]Xu W,Wang Y,Wang J,et al.Long-term administration of bisphosphonate to reduce local recurrence of sacral giant cell tumor after nerve-sparing surgery[J].J Neurosurg Spine,2017,26(6):716-721.
• [19]Chen KH,Wu PK,Chen CF,et al.Zoledronic acid-loaded bone cement as a local adjuvant therapy for giant cell tumor of the sacrum after intralesional curettage[J].Eur Spine J,2015,24(10):2182-2188.
• [20]Andronis L,Goranitis I,Bayliss S,et al.Cost-effectiveness of treatments for the management of bone metastases:a systematic literature review[J].Pharmacoeconomics,2017,36(3):301-322.
• [21]Yang H,Qiu L,Zhang L,et al.Platinum-zoledronate complex blocks gastric cancer cell proliferation by inducing cell cycle arrest and apoptosis[J].Tumour Biol,2016,37(8):10981-10992.
• [22]Nienhuis HH,Arjaans M,Timmer-Bosscha H,et al.Human stromal cells are required for an anti-breast cancer effect of zoledronic acid[J].Oncotarget,2015,6(27):24436-24447.
• [23]Fragni M,Bonini SA,Bettinsoli P,et a.The mi R-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines[J].Naunyn Schmiedebergs Arch Pharmacol,2016,389(5):529-538.
• [24]Suratwala SJ,Cho SK,van Raalte JJ,et al.Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite[J].J Bone Joint Surg Am,2008,90(10):2189-2196.
• [25]Jakobsen T,Kold S,Shiguetomi-Medina J,et al.Topical zoledronic acid decreases micromotion induced bone resorption in a sheep arthroplasty model[J].BMC Musculoskelet Disord,2017,18(1):441.
• [26]Scott DF,Woltz JN,Smith RR.Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty:preliminary results of a prospective randomized trial[J].J Arthroplasty,2013,28(4):671-675.
• [27]袁宏,陆琳松,钟惠琴,等.唑来膦酸对骨质疏松患者全髋关节置换术后假体周围骨密度的影响[J].中华关节外科杂志(电子版),2014,8(3):3-8.
• [28]Jakobsen T,Bechtold JE,S?balle K,et al.Local delivery of zoledronate from a poly(d,l-lactide)-coating increases fixation of hydroxy-coated implants[J].J Orthop Res,2017,35(5):974-979.
• [29]Jakobsen T,Bechtold JE,S?balle K,et al.Local delivery of zoledronate from a poly(D,L-lactide)-Coating increases fixation of press-fit implants[J].J Orthop Res,2016,34(1):65-71.
• [30]Kellesarian SV,Subhi AL,Harthi S,et al.Effect of local zoledronate delivery on osseointegration:a systematic review of preclinical studies[J].Acta Odontol Scand,2017,75(7):530-541.
• [31]Lee YK,Ha YC,Cho YJ,et al.Does zoledronate prevent femoral head collapse from osteonecrosis?A prospective,randomized,open-label,multicenter study[J].J Bone Joint Surg Am,2015,97(14):1142-1148.
• [32]Johannesen J,Briody J,Mc Quade M,et al.Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease[J].Bone,2009,45(5):898-902.
• [33]Young ML,Little DG,Kim HK.Evidence for using bisphosphonate to treat Legg-Calvé-Perthes disease[J].Clin Orthop,2012,470(9):2462-2475.
• [34]Muehleman C,Green J,Williams JM,et al.The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage[J].Osteoarthritis Cartilage,2002,10:226-233.
• [35]Strassle BW,Mark L,Leventhal L,et al.Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease[J].Osteoarthritis Cartilage,2010,18:1319-1328.
• [36]Lampropoulou-Adamidou K,Dontas I,Stathopoulos IP,et al.Chondroprotective effect of high-dose zoledronic acid:an experimental study in a rabbit model of osteoarthritis[J].J Orthop Res,2014,32(12):1646-1651.
• [37]C?nar BM,Ozkoc G,Bolat F,et al.Intra-articular zoledronic acid in a rat osteoarthritis model:significant reduced synovitis may indicate chondroprotective effect[J].Knee Surg Sports Traumatol Arthrosc,2015,23(5):1410-1418.
• [38]Dearmin MG,Trumble TN,García A,et al.Chondroprotective effects of zoledronic acid on articular cartilage in dogs with experimentally induced osteoarthritis[J].Am J Vet Res,2014,75(4):329-337.
• [39]Ozenci AM,Aslan T,Sahin Z,et al.Protective effect of zoledronic acid on corticosteroid-induced chondrocyte apoptosis in rat articular cartilage[J].Acta Orthop Traumatol Turc,2013,47(6):430-435.
• [40]Yu DG,Yu B,Mao YQ,et al.Efficacy of zoledronic acid in treatment of teoarthritis is dependent on the disease progression stage in rat medial meniscal tear model[J].Acta Pharmacol Sin,2012,33(7):924-934.
• [41]She G,Zhou Z,Zha Z,et al.Protective effect of zoledronic acid on articular cartilage and subchondral bone of rabbits with experimental knee osteoarthritis[J].Exp Ther Med,2017,14(5):4901-4909.